Alembic Pharmaceuticals receives USFDA approval for Amantadine Hydrochloride Capsules
DSIJ Intelligence / 22 Jun 2017
On Thursday, Alembic Pharmaceuticals announced that it has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Amantadine Hydrochloride Capsules, USP, 100 mg.
On Thursday, Alembic Pharmaceuticals announced that it has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Amantadine Hydrochloride Capsules, USP, 100 mg.
Alembic Pharmaceuticals Limited is engaged in developing formulations and active pharmaceutical ingredients (API). The company focuses on therapies such as orthopaedic, cardiology, diabetes, gynaecology, gastrointestinal, dermatology and ophthalmology.
Amantadine Hydrochloride Capsules are indicated for the treatment of Parkinsonism and drug-induced extrapyramidal reactions.
Meanwhile, at Rs 540 per share at 0936 hours on BSE, Alembic Pharmaceuticals was trading up by 1.5%. It hit a high of Rs 543 and a low of Rs 538.05, so far in the morning session.
The stock has underperformed BSE Mid-cap and BSE Healthcare Index over a period of one year. Its closest peers are Torrent Pharmaceuticals and Alkem Laboratories.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.